Morbid obesity is associated with mortality and acute kidney injury in hospitalized patients with COVID-19.
Acute kidney injury
COVID-19
Morbid obesity
Mortality
Journal
Clinical nutrition ESPEN
ISSN: 2405-4577
Titre abrégé: Clin Nutr ESPEN
Pays: England
ID NLM: 101654592
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
04
05
2021
revised:
30
07
2021
accepted:
23
08
2021
entrez:
8
10
2021
pubmed:
9
10
2021
medline:
15
10
2021
Statut:
ppublish
Résumé
Mexico has one of the highest mortality rates by COVID-19 worldwide. This may be partially explained by the high prevalence of overweight/obesity found in general population; however, there is limited information in this regard. Furthermore, acute kidney injury (AKI) and need for renal replacement therapy (RRT) associated to obesity in patients with COVID-19 are still topics of discussion. To explore the association of obesity, particularly morbid obesity, with mortality and kidney outcomes in a Mexican population of hospitalized patients with COVID-19. Retrospective cohort study of 773 patients with COVID-19 hospitalized in a tertiary-care teaching hospital in the Mexican state of Jalisco. Baseline body mass index was classified as: normal weight (18.5-24.9 kg/m At baseline, 35% of patients had overweight, 39% obesity and 8% morbid obesity. Patients with obesity were younger, more frequently women and with hypertension than normal weight and overweight patients. Frequency of complications in the univariate analysis were not significantly associated to obesity, however in the multivariate analysis (after adjusting for baseline clinical and biochemical differences), morbid obesity was significantly associated to an increased risk of AKI [OR = 2.70 (1.01-7.26), p = 0.05], RRT [OR = 14.4 (1.46-42), p = 0.02], and mortality [OR = 3.54 (1.46-8.55), p = 0.005]. Almost half of the sample had obesity and morbid obesity. Morbid obesity was significantly associated to an increased risk of AKI, RRT and mortality in hospitalized patients with COVID-19.
Sections du résumé
BACKGROUND & AIMS
Mexico has one of the highest mortality rates by COVID-19 worldwide. This may be partially explained by the high prevalence of overweight/obesity found in general population; however, there is limited information in this regard. Furthermore, acute kidney injury (AKI) and need for renal replacement therapy (RRT) associated to obesity in patients with COVID-19 are still topics of discussion.
AIM
To explore the association of obesity, particularly morbid obesity, with mortality and kidney outcomes in a Mexican population of hospitalized patients with COVID-19.
METHODS
Retrospective cohort study of 773 patients with COVID-19 hospitalized in a tertiary-care teaching hospital in the Mexican state of Jalisco. Baseline body mass index was classified as: normal weight (18.5-24.9 kg/m
RESULTS
At baseline, 35% of patients had overweight, 39% obesity and 8% morbid obesity. Patients with obesity were younger, more frequently women and with hypertension than normal weight and overweight patients. Frequency of complications in the univariate analysis were not significantly associated to obesity, however in the multivariate analysis (after adjusting for baseline clinical and biochemical differences), morbid obesity was significantly associated to an increased risk of AKI [OR = 2.70 (1.01-7.26), p = 0.05], RRT [OR = 14.4 (1.46-42), p = 0.02], and mortality [OR = 3.54 (1.46-8.55), p = 0.005].
CONCLUSIONS
Almost half of the sample had obesity and morbid obesity. Morbid obesity was significantly associated to an increased risk of AKI, RRT and mortality in hospitalized patients with COVID-19.
Identifiants
pubmed: 34620318
pii: S2405-4577(21)00315-6
doi: 10.1016/j.clnesp.2021.08.027
pmc: PMC8413095
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
200-205Informations de copyright
Copyright © 2021 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest Authors declare no conflict of interest.
Références
Clin Infect Dis. 2016 Sep 1;63(5):e61-e111
pubmed: 27418577
PLoS One. 2021 Feb 19;16(2):e0245394
pubmed: 33606711
Rev Invest Clin. 2020;72(4):252-258
pubmed: 33064701
PLoS One. 2021 Feb 8;16(2):e0246595
pubmed: 33556150
Int J Obes (Lond). 2020 Sep;44(9):1832-1837
pubmed: 32712623
PLoS One. 2020 Nov 18;15(11):e0237799
pubmed: 33206653
World Health Organ Tech Rep Ser. 1995;854:1-452
pubmed: 8594834
Gerontology. 2021;67(3):255-266
pubmed: 33406518
Physiol Rev. 2013 Jan;93(1):1-21
pubmed: 23303904
Salud Publica Mex. 2020 Nov-Dec;62(6):614-617
pubmed: 33620959
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Nat Rev Endocrinol. 2019 May;15(5):288-298
pubmed: 30814686
Obes Rev. 2020 Nov;21(11):e13128
pubmed: 32845580
Blood Purif. 2010;29(2):150-7
pubmed: 20093821
Immun Ageing. 2021 Jan 4;18(1):1
pubmed: 33390183
Am J Kidney Dis. 2021 Feb;77(2):204-215.e1
pubmed: 32961245
Cleve Clin J Med. 2020 Jan;87(1):53-64
pubmed: 31990655
J Intensive Care Med. 2020 Oct;35(10):963-970
pubmed: 32812834
Int Urol Nephrol. 2017 Mar;49(3):461-466
pubmed: 27822672
Crit Care. 2020 Jun 18;24(1):356
pubmed: 32552872
Rev Invest Clin. 2020;72(3):151-158
pubmed: 32584330
J Med Virol. 2021 Feb;93(2):1188-1193
pubmed: 32975814
J Obes. 2021 Jan 22;2021:8837319
pubmed: 33542836
Kidney Int. 2020 Jul;98(1):209-218
pubmed: 32416116
Clin Kidney J. 2020 Sep 02;13(4):550-563
pubmed: 32897278
JAMA. 2016 Feb 23;315(8):762-74
pubmed: 26903335
Clin J Am Soc Nephrol. 2020 Dec 31;16(1):14-25
pubmed: 33199414
J Am Soc Nephrol. 2016 May;27(5):1270-2
pubmed: 26598516
Am J Med Sci. 1999 Nov;318(5):293-7
pubmed: 10555090
Diabetes Metab. 2021 Mar;47(2):101178
pubmed: 32738402